DEF 14A: Serina Therapeutics Seeks Stockholder Approval for Equity Incentive Plan Amendment

Serina Therapeutics is asking stockholders to approve an amendment to its 2024 Equity Incentive Plan to increase the share reserve and introduce an evergreen provision.

Summary

• Serina Therapeutics is holding its Annual Meeting of Stockholders on December 13, 2024, to elect directors, ratify the appointment of Frazier & Deeter, LLC as independent registered public accountants, and approve an amendment to the Serina Therapeutics, Inc. 2024 Equity Incentive Plan.
• The proposed amendment includes increasing the number of shares available for issuance under the plan to 2,675,000, increasing the number of shares that may be issued as Incentive Stock Options to 2,675,000, and introducing an evergreen provision.
• The evergreen provision would automatically increase the share reserve by 5% of the outstanding shares of common stock on the last day of the preceding fiscal year, starting in 2026 and ending in 2034, unless the Board acts to reduce or eliminate the increase.
• The amendment also modifies the Reversion of Shares Provisions.
• As of October 22, 2024, there were 8,891,976 shares of Serina common stock outstanding.
• As of October 22, 2024, there were approximately 72,208 shares remaining available for issuance under the 2024 Incentive Plan, 1,652,792 total stock options outstanding (with associated weighted average exercise price of $7.95 and weighted average remaining term of 9.74 years).

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, outlining the agenda for the annual meeting and seeking approval for routine matters. The proposed equity incentive plan amendment is generally viewed positively as a tool for attracting and retaining talent, but there are potential dilution concerns.

Positives

• The proposed amendment to the 2024 Equity Incentive Plan is designed to attract and retain key personnel by providing stock-based compensation.
• The evergreen provision allows for a consistent replenishment of shares available for issuance, ensuring the company can continue to incentivize employees and directors.
• The Board has the discretion to adjust or eliminate the evergreen increase, providing flexibility in managing the share reserve.
• The modification of the Reversion of Shares Provisions could make the plan more efficient in terms of share usage.

Negatives

• Increasing the share reserve could dilute existing stockholders' ownership.
• The evergreen provision, while beneficial for incentivizing employees, could lead to increased dilution over time if not managed carefully.
• The Board's discretion to adjust the evergreen increase could be viewed as a lack of transparency or predictability.

Risks

• Failure to obtain stockholder approval for the 2024 Incentive Plan Amendment could limit the company's ability to attract and retain key personnel.
• Over-issuance of equity awards could lead to excessive dilution and negatively impact the stock price.
• Changes in tax laws could affect the attractiveness of stock options and other equity awards.
• The company's performance may not justify the level of equity compensation being granted, leading to dissatisfaction among stockholders.

Future Outlook

The company intends to continue granting equity awards to employees, non-employee directors, and consultants at levels determined by the Board to be necessary to attract, retain and motivate individuals critical to the company's success.

Management Comments

• Steve Ledger, Chief Executive Officer, invites stockholders to attend the Annual Meeting and encourages them to sign and return the proxy card.

Industry Context

The use of equity incentive plans is a common practice in the biotechnology industry to attract and retain talent, aligning their interests with those of the company's stockholders. The proposed amendment to increase the share reserve and introduce an evergreen provision is consistent with this industry trend.

Comparison to Industry Standards

• Comparing Serina's equity incentive plan to those of similar-sized biotechnology companies reveals common practices.
• For example, companies like Madrigal Pharmaceuticals and Viking Therapeutics, which are also clinical-stage biopharmaceutical firms, utilize equity compensation extensively.
• Madrigal's plan allows for evergreen increases of 4% of outstanding shares, while Viking's plan has a fixed share reserve with periodic increases.
• Serina's proposed 5% evergreen increase is slightly more aggressive than Madrigal's but within a reasonable range for incentivizing growth.
• The vesting schedules and types of awards (stock options, RSUs) are also consistent with industry norms, ensuring competitive compensation packages.

Stakeholder Impact

• Approval of the equity incentive plan amendment could impact shareholders through potential dilution.
• Employees and directors could benefit from the increased availability of equity awards.
• The company's long-term success could be enhanced by attracting and retaining key personnel.

Next Steps

• Stockholders are urged to review the proxy statement and vote on the proposals.
• The company will hold the Annual Meeting of Stockholders on December 13, 2024.
• The Board will implement the approved proposals following the Annual Meeting.

Key Dates

Keywords

equity incentive plan, annual meeting, stockholders, directors, proxy statement, compensation, stock options, Serina Therapeutics, amendment, shares